# EDGAR Filing Document

**Accession Number:** 0001965743
**File Stem:** 0001094891-26-000168
**Filing Date:** 2026-4
**Character Count:** 5197
**Document Hash:** 5c8cbce8a9e975b72edfa74162c9773d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001094891-26-000168.hdr.sgml**: 20260406

**ACCESSION NUMBER**: 0001094891-26-000168

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260327

**FILED AS OF DATE**: 20260406

**DATE AS OF CHANGE**: 20260406

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Tasso Partners, LLC
- **CENTRAL INDEX KEY:** 0001965743

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37685
- **FILM NUMBER:** 26842779

**BUSINESS ADDRESS:**
- **STREET 1:** P.O. BOX 503
- **CITY:** RUMSON
- **STATE:** NJ
- **ZIP:** 07760
- **BUSINESS PHONE:** 347-986-0729

**MAIL ADDRESS:**
- **STREET 1:** P.O. BOX 503
- **CITY:** RUMSON
- **STATE:** NJ
- **ZIP:** 07760
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PAVmed Inc.
- **CENTRAL INDEX KEY:** 0001624326
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 471214177
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** (212) 949-4319

**MAIL ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PAXmed Inc.
- **DATE OF NAME CHANGE:** 20141105

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Tasso Partners, LLC<br><sub>(Last) (First) (Middle)</sub><br>P.O. BOX 6194<br><sub>(Street)</sub><br>FAIR HAVEN, NJ 07704<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>PAVmed Inc. [ PAVM ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-27 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 912996 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Warrants<sup>(1)</sup> | 2026-02-03 | 2031-02-03 | Series D Preferred Stock | 5365<sup>(1)</sup> | 1000<sup>(1)</sup> | D |  |

---

### Footnotes:

(1) The Warrant entitles the reporting person to purchase up to 5,365 shares of Series D Preferred Stock at an exercise price of $1,000 per share. Each share of Series D Preferred Stock has a stated value of $1,000 per share and is convertible into shares of Common Stock at a conversion price of $6.50 per share, for an aggregate of up to 825,385 shares of Common Stock. Upon exercise of the Warrant, the Issuer may, in lieu of issuing the Series D Preferred Stock, issue to the reporting person the number of shares of Common Stock that would be issuable to the holder upon conversion of the Series D Preferred Stock.

**Signature:** /s/ Dana Carrera, as manager of managing member  
**Date:** 2026-04-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**